Jessica Seeliger, PhD
Research Awards Nationwide Recipient (2013-2015)
State University of New York, Stony Brook, NY
Funded in Partnership with support from the Mary Fuller Russell Research Fund
Targeting Latent and Multi-Drug Resistant TB
Mycobacterium tuberculosis (Mtb), infects one-third of the world's population. Most infected individuals have latent TB infections and have no symptoms. However, decreased immune responses can trigger latent TB to reactivate and cause infectious disease. Some TB disease can become resistant to first line medications and therefore, new therapies are needed to treat multi- and extremely drug-resistant TB strains. Dr. Seeliger and team will use a novel chemical method to evaluate a family of Mtb enzymes with diverse functions essential for bacterial survival as potential drug targets. These enzymes may be promising for developing next-generation therapies against latent infections and multi-drug resistant TB
Sign up for the latest lung health news delivered right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.